STOCK TITAN
  1. Home
  2. News
  3. BDRX

Biodexa Pharmaceuticals Plc - BDRX STOCK NEWS

Welcome to our dedicated news page for Biodexa Pharmaceuticals Plc (Ticker: BDRX), a resource for investors and traders seeking the latest updates and insights on Biodexa Pharmaceuticals Plc.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Biodexa Pharmaceuticals Plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Biodexa Pharmaceuticals Plc's position in the market.

News
Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP)
Rhea-AI Summary
<p>Biodexa Pharmaceuticals PLC announced entering into an exclusive license agreement with Rapamycin Holdings Inc. for the rights to eRapa, a Phase 3 ready asset for the treatment of Familial Adenomatous Polyposis (FAP). The deal includes $17 million in non-dilutive grant funding for a pivotal Phase 3 trial in FAP. FAP affects an estimated 100,000 individuals in the U.S. and Europe, leading to precancerous polyps and often requiring surgical intervention. eRapa shows promise in delaying or preventing the need for surgery. The Phase 3 FAP program is backed by a $17 million grant from CPRIT. Biodexa is focused on developing innovative treatments for diseases with unmet medical needs, with ongoing studies in bladder cancer and other potential indications.</p>
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News
Preliminary Results for the Year Ended 31 December 2023
Rhea-AI Summary
Biodexa Pharmaceuticals PLC announces audited preliminary results for the year ended 31 December 2023, showcasing progress in developing products for brain cancers. The company, listed as NASDAQ: BDRX, is a clinical stage biopharmaceutical firm.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.3%
Tags
none
-
News
Biodexa's MTX110 Shows Promise In Extending Life Expectancy Against Aggressive Brain Cancers
Rhea-AI Summary
Biodexa Pharmaceuticals (BDRX) is developing MTX110 for Diffuse Midline Glioma (DMG) and Recurrent Glioblastoma (rGBM), two aggressive brain cancers with poor prognoses. Early trials show promise in extending survival rates. MTX110 combines a water-soluble form of panobinostat with Convection Enhanced Delivery (CED) technology to target brain tumors directly. Phase 1 trials for DMG and rGBM patients have shown encouraging results, with potential to extend patient life and minimize side effects.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
88.59%
Tags
none
News
Biodexa Takes Aim At Type 1 Diabetes With Innovative Drug Candidate Tolimidone
Rhea-AI Summary
A new orally dosed small molecule candidate aims to reduce or eliminate the need for injectable insulin, with topline data from its Phase 2a program expected by year-end. The safety profile has been established in over 700 patients, targeting the 1.3 million U.S. adults with type 1 diabetes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.09%
Tags
none
-
News
Biodexa Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D Update
Rhea-AI Summary
Biodexa Pharmaceuticals PLC announces positive top-line Phase I clinical trial results for diffuse midline glioma (DMG) with a median overall survival of 16.5 months compared to 10.0 months in a comparable cohort. The company also provides an R&D update on tolimidone's potential for beta cell proliferation in an in vitro model.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.25%
Tags
clinical trial
-
News
Biodexa Reports 12 Month Survival in MAGIC-G1 Study of MTX110 in Recurrent Glioblastoma Patients
Rhea-AI Summary
Biodexa Pharmaceuticals PLC reports 12-month survival in the MAGIC-G1 study of MTX110 in recurrent glioblastoma patients. The study is being conducted at Duke Cancer Institute and Baptist MD Anderson Cancer Center. No drug-related adverse events were observed within the first 30 days from the start of treatment. Patient #1 received weekly infusions of 60µM of MTX110 and survived for 12 months from the start of treatment. Patients #2, 3, and 4 each received weekly infusions of 90µM of MTX110, the expected optimum dose, and remain in the study. GBM universally recurs, and once it does, the median overall survival is 6.5 months. Currently, no standard of care is established for rGBM.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.7%
Tags
none
News
Biodexa Announces Allowance of U.S. Patent Covering Tolimidone
Rhea-AI Summary
Biodexa Pharmaceuticals PLC announced the allowance of a U.S. patent covering Tolimidone, a drug intended for the treatment of Type 1 diabetes. The company plans to initiate a Phase 2 clinical program following successful preclinical studies. The safety profile of Tolimidone has been established in prior human studies of over 700 patients. The U.S. Patent and Trademark Office allowed the patent application, providing market exclusivity for Tolimidone in the U.S. Biodexa's CEO and CFO, Stephen Stamp, expressed optimism about the potential of Tolimidone in the treatment of Type 1 diabetes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.76%
Tags
none
-
News
Biodexa CEO Issues Shareholder Letter Highlighting Progress in 2023 and Expected Milestones in 2024
Rhea-AI Summary
Biodexa Pharmaceuticals PLC CEO issued a shareholder letter highlighting the company's progress in 2023 and expected milestones in 2024. The company transitioned to a NASDAQ-listed, multi-asset therapeutics company and in-licensed a new molecule for Type I diabetes. The pipeline includes Phase II ready asset for Type 1 diabetes, a unique formulation for recurrent glioblastoma multiforme, diffuse midline glioma, and a preclinical program for leptomeningeal disease. The company aims to deliver two sets of preclinical data and three sets of clinical data in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.24%
Tags
none
-
News
Biodexa Appoints Ann Merchant to the Board of Directors
Rhea-AI Summary
Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) appoints Ann Merchant as Non-executive Director to the Board of Directors. Ann Merchant brings extensive international operations experience from her roles at MorphoSys, Schreiner Medipharm, and Amgen. Dr. Stephen Parker, Chairman of Biodexa, expresses his excitement about Ann Merchant's appointment, highlighting her ability to bring a different perspective to the Board.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.9%
Tags
management
News
Biodexa Announces Closing Of $6.0 Million Underwritten Public Offering, Including Full Exercise Of Overallotment Option
Rhea-AI Summary
Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) closes $6.0 million underwritten public offering and acquires exclusive, worldwide license to Tolimidone for Type I Diabetes clinical program
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.58%
Tags
offering
Stock BDRX logo
Biodexa Pharmaceuticals Plc

Nasdaq:BDRX

BDRX Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

BDRX Stock Data

3.66M
106.44M
10.26%
19.54%
1.57%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United Kingdom
Abingdon

About BDRX

midatech is a world leader in the design, synthesis and manufacture of biocompatible gold nanoparticles (gnps) with a core focus on therapeutics for diabetes and cancer. midatech has a strong pipeline of product candidates in clinical and pre-clinical development for the treatment of diabetes and various cancers. in 2012, midatech established midasol therapeutics lp, a strategic joint venture with monosol rx llc to focus on the development and commercialization, via partnering or licensing, of products primarily for the treatment of diabetes. midasol’s lead product, midaform™ insulin pharmfilm, is a unique product for the oral delivery of insulin in diabetic patients and will enter phase ii clinical studies in 2014. these technologies are also being evaluated in the diabetes area by a major us pharmaceutical company. midatech’s unique gnp technology enables the administration and targeted delivery of therapeutic compounds to specific cells and tissues. multiple drug molecules can b